| Description | Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of
the World Economic Forum Technology Pioneer Award, the Company has patented the
derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and
cardiomyocyte cell precursors (CCP-01) from a synergetic cell population that is sourced
from the patients blood. The Company is selling exempt compassionate treatments to
individuals afflicted with critical limb ischemia, for example, and conducting clinical trials
to commercialize its lead product, ACP-01, for the treatment of cardiovascular disease
including chronic limb threatening ischemia (CLTI), peripheral arterial disease, Angina,
hardening of the arteries (Ischemic Cardiomyopathy) thickening of the heart wall (Dilated
Cardiomyopathy) and Congestive Heart Failure.
Additional info from OTC:
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of
the World Economic Forum Technology Pioneer Award, the Company has patented the
derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and
cardiomyocyte cell precursors (CCP-01) from a synergetic cell population that is sourced
from the patients blood. The Company is selling exempt compassionate treatments to
individuals afflicted with critical limb ischemia, for example, and conducting clinical trials
to commercialize its lead product, ACP-01, for the treatment of cardiovascular disease
including chronic limb threatening ischemia (CLTI), peripheral arterial disease, Angina,
hardening of the arteries (Ischemic Cardiomyopathy) thickening of the heart wall (Dilated
Cardiomyopathy) and Congestive Heart Failure. |
|---|